Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""lenalidomide"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 6873
Tytuł:
Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1.
Autorzy:
Liang X; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, Shandong, China.; School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Shi H; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, Shandong, China.
Bi K; Department of Hematology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Feng S; Department of Hematology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Chen S; School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Zhao W; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, Shandong, China.
Huang X; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, Shandong, China. .; School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 31; Vol. 14 (1), pp. 2577. Date of Electronic Publication: 2024 Jan 31.
Typ publikacji:
Journal Article
MeSH Terms:
ATP Binding Cassette Transporter, Subfamily B*/genetics
Lenalidomide*/adverse effects
Lenalidomide*/pharmacokinetics
East Asian People*/genetics
Humans ; China ; Genotype ; Polymorphism, Single Nucleotide
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect.
Autorzy:
Wu J; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Wang X; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Zhang M; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Mathews P; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Aug 03; Vol. 12 (15). Date of Electronic Publication: 2023 Aug 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Lenalidomide*/pharmacology
Lenalidomide*/therapeutic use
Multiple Myeloma*/drug therapy
Retinoid X Receptors*/agonists
Animals ; Humans ; Mice ; Glucose ; Peroxisome Proliferator-Activated Receptors ; T-Lymphocytes
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Autorzy:
Osada N; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
Kikuchi J; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
Iha H; Division of Pathophysiology, The Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Oita, Japan.
Yasui H; Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.; Project Division of Innovative Diagnostics Technology Platform, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Ikeda S; Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Takahashi N; Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Furukawa Y; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.; Center for Medical Education, Teikyo University of Science, Tokyo, Japan.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Aug; Vol. 13 (8), pp. e1364.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ikaros Transcription Factor*/genetics
Ikaros Transcription Factor*/metabolism
Lenalidomide*/pharmacology
Lenalidomide*/therapeutic use
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Drug Resistance, Neoplasm*
Proto-Oncogene Proteins c-fos*/genetics
Proto-Oncogene Proteins c-fos*/metabolism
Animals ; Humans ; Mice ; Bone Marrow ; Trans-Activators/therapeutic use ; Transcription Factor AP-1/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
POEMS syndrome: origination from clonal plasma cells or B cells?
Autorzy:
Zhou L; Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Lu J; Department of Hematology, Affiliated Hospital of Nantong University, Medical School Nantong University, Nantong, 226001, People's Republic of China.
Lin Z; Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Wang X; Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Luo L; Department of Geriatrics, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Wang C; Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Hong L; Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Xu R; Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Huang H; Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2186044.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
POEMS Syndrome*/therapy
POEMS Syndrome*/drug therapy
Aged ; Humans ; Male ; Lenalidomide/therapeutic use ; Remission Induction ; Vascular Endothelial Growth Factor A/therapeutic use ; B-Lymphocytes
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Autorzy:
Mitchell JL; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK.; Institute for Cardiovascular Research, University of Birmingham, Birmingham, UK.
Khan D; Blood Theme Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Rana RH; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK.
Kriek N; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK.
Unsworth AJ; Department of Life Sciences, Manchester Metropolitan University, Manchester, UK.
Sage T; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK.
Bye AP; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK.
Laffan M; Centre for Haematology, Department of Medicine, Imperial College London, London, UK.
Shapiro S; Blood Theme Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Radcliffe Department of Medicine, Oxford University, Oxford, UK.
Thakurta A; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.
Grech H; Department of Haematology, Royal Berkshire Hospitals NHS Foundation Trust, Reading, UK.
Ramasamy K; Blood Theme Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Gibbins JM; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK.
Pokaż więcej
Źródło:
Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2264940. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/complications
Thrombosis*/complications
Monoclonal Gammopathy of Undetermined Significance*/complications
Humans ; Lenalidomide/pharmacology ; Lenalidomide/therapeutic use ; Pilot Projects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Autorzy:
Shang Y; Shandong First Medical University & Shandong Academy of Medical Sciences, Shandong, China
Zhao H; Central Hospital Affiliated to Shandong First Medical University, Shandong, China
Li D; Central Hospital Affiliated to Shandong First Medical University, Shandong, China
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Dec 05; Vol. 40 (4), pp. 284-285. Date of Electronic Publication: 2023 Sep 01.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Lenalidomide/adverse effects ; Rituximab/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Autorzy:
Noel R; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Zemmour C; Department of Clinical Research and Innovation - Biostatistics & Methodology Unit, Marseille, France.; Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Montes de Oca C; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Belmecheri N; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Aurran-Schleinitz T; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Coso D; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Lopez Almeida L; Department of Clinical Research and Innovation - Sponsoring Unit, Institut Paoli-Calmettes, Marseille, France.
Mescam L; Department of Pathology, Institut Paoli-Calmettes, Marseille, France.
Vey N; Department of Hematology, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France.
Bladé JS; Department of Oncology and Hematology, Sainte Anne Military Hospital, Toulon, France.
Slama B; Department of Hematology, Centre Hospitalier Raoul Follereau, Avignon, France.
Bouabdallah R; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Schiano de Colella JM; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2207948.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Large B-Cell, Diffuse*
Humans ; Aged ; Rituximab/adverse effects ; Lenalidomide/adverse effects ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Autorzy:
DerSarkissian M; Analysis Group, Boston, MA, USA.
Cranmer H; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Dabora J; Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.
Bocharova I; Analysis Group, Boston, MA, USA.
Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Cheng M; Analysis Group, Boston, MA, USA.
Bhak RH; Analysis Group, Boston, MA, USA.
Duh MS; Analysis Group, Boston, MA, USA.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2156731.
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Multiple Myeloma*/drug therapy
Humans ; Bayes Theorem ; Dexamethasone/therapeutic use ; Lenalidomide/therapeutic use ; Network Meta-Analysis ; Systematic Reviews as Topic ; Randomized Controlled Trials as Topic ; Observational Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Autorzy:
Kauer J; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.
Freundt EP; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Schmitt A; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Weinhold N; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Mai EK; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany.
Müller-Tidow C; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Goldschmidt H; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Raab MS; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Kriegsmann K; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Laborarztpraxis, Laborarztpraxis Rhein-Main MVZ GbR, Limbach Gruppe SE, Frankfurt Am Main, Germany.
Sauer S; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 21; Vol. 23 (1), pp. 1132. Date of Electronic Publication: 2023 Nov 21.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Heterocyclic Compounds*/therapeutic use
Multiple Myeloma*/drug therapy
Multiple Myeloma*/diagnosis
Peripheral Blood Stem Cell Transplantation*
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Hematopoietic Stem Cell Mobilization/methods ; Lenalidomide/therapeutic use ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
Autorzy:
Tekinalp A; Necmettin Erbakan University Meram Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye
Gedük A; Kocaeli University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Kocaeli, Türkiye
Akdeniz A; Mersin University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Mersin, Türkiye
Terzi Demirsoy E; University of Health Sciences Türkiye, Derince Training and Research Hospital, Clinic of Hematology, Kocaeli, Türkiye
Gürsoy V; Bursa City Hospital, Clinic of Hematology, Bursa, Türkiye
Aslaner Ak M; Bülent Ecevit University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Zonguldak, Türkiye
Bağcı M; Selçuk University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye
Seçilmiş S; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Hematology, Ankara, Türkiye
Keklik Karadağ F; Ege University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, İzmir, Türkiye
Oruç Uysal A; Fırat University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Elazığ, Türkiye
Doğan A; Van Yüzüncü Yıl University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Van, Türkiye
Demircioğlu S; Necmettin Erbakan University Meram Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye
Erol HA; Kocaeli University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Kocaeli, Türkiye
Aslan C; University of Health Sciences Türkiye, Derince Training and Research Hospital, Clinic of Hematology, Kocaeli, Türkiye
Özkalemkaş F; Bursa Uludağ University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Bursa, Türkiye
Ertop Ş; Bülent Ecevit University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Zonguldak, Türkiye
Dağlı M; Selçuk University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye
Dal MS; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Hematology, Ankara, Türkiye
Saydam G; Ege University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, İzmir, Türkiye
Merter M; Fırat University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Elazığ, Türkiye
Ural C; Van Yüzüncü Yıl University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Van, Türkiye
Çeneli Ö; Necmettin Erbakan University Meram Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Dec 05; Vol. 40 (4), pp. 242-250. Date of Electronic Publication: 2023 Nov 14.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Female ; Humans ; Male ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/therapeutic use ; Lenalidomide/therapeutic use ; Neutropenia ; Retrospective Studies ; Adult ; Middle Aged ; Aged ; Aged, 80 and over
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma.
Autorzy:
Mioso G; Unit of Dermatology, Department of Medicine (DIMED), University of Padova, 35128 Padua Italy.
Gnesotto L; Unit of Dermatology, Department of Medicine (DIMED), University of Padova, 35128 Padua Italy.
Russo I; Unit of Dermatology, Department of Medicine (DIMED), University of Padova, 35128 Padua Italy.; Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, IOV- IRCCS, 35128 Padua, Italy.
Piaserico S; Unit of Dermatology, Department of Medicine (DIMED), University of Padova, 35128 Padua Italy.
Alaibac M; Unit of Dermatology, Department of Medicine (DIMED), University of Padova, 35128 Padua Italy.
Pokaż więcej
Źródło:
The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2182619.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*
Psoriasis*
Humans ; Lenalidomide ; Thalidomide ; Patients
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
Autorzy:
Chen H; Department of Hematology and Oncology, Zhabei Central Hospital, Shanghai, People's Republic of China.
Chen H; Department of Plastic Surgery, Zhoushan Hospital of Traditional Chinese Medicine, Zhoushan, People's Republic of China.
Zhou Y; Department of Hematology and Oncology, Zhabei Central Hospital, Shanghai, People's Republic of China.
Xu W; Department of Hematology and Oncology, Zhabei Central Hospital, Shanghai, People's Republic of China.
Yu J; Department of Hematology and Oncology, Zhabei Central Hospital, Shanghai, People's Republic of China.
Xu Y; Department of Hematology and Oncology, Zhabei Central Hospital, Shanghai, People's Republic of China.
Zhou F; Department of Hematology and Oncology, Zhabei Central Hospital, Shanghai, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2225342.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Humans ; Lenalidomide/therapeutic use ; Network Meta-Analysis ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan.
Autorzy:
Hagiwara H; Department of Medical Innovation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nakayama T; Department of Cardiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hashimoto H; Department of Clinical Research Management Center, Nagoya City University Hospital, Nagoya, Japan.
Kusumoto S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Fukuta H; Department of Clinical Research Management Center, Nagoya City University Hospital, Nagoya, Japan.
Kamiya T; Department of Clinical Research Management Center, Nagoya City University Hospital, Nagoya, Japan.
Ikuta K; Laboratory of Immune Regulation, Department of Virus Research, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Oct; Vol. 12 (19), pp. 19361-19371. Date of Electronic Publication: 2023 Sep 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/epidemiology
Humans ; Lenalidomide ; Japan/epidemiology ; Retrospective Studies ; Dexamethasone ; Risk Factors ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
Autorzy:
Sugi T; Department of Pharmacy, Eiju General Hospital, Taito-ku, Japan.; Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan.
Mita M; Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan.
Yasu T; Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Kiyose, Japan.
Ohara S; Department of Hematology, Eiju General Hospital, Taito-ku, Japan.
Uchida T; Department of Hematology, Eiju General Hospital, Taito-ku, Japan.
Inoue M; Department of Hematology, Eiju General Hospital, Taito-ku, Japan.
Hagihara M; Department of Hematology, Eiju General Hospital, Taito-ku, Japan.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2021 Dec; Vol. 46 (6), pp. 1792-1795. Date of Electronic Publication: 2021 May 07.
Typ publikacji:
Case Reports
MeSH Terms:
Exanthema/*chemically induced
Exanthema/*therapy
Lenalidomide/*therapeutic use
Multiple Myeloma/*drug therapy
Aged ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Patient Acuity
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.
Autorzy:
Guinn BA; Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.
Schuler PJ; Department of Otorhinolaryngology, University Hospital Ulm, 89081 Ulm, Germany.
Schrezenmeier H; Institute of Transfusion Medicine, University of Ulm and German Red Cross, 89073 Ulm, Germany.
Hofmann S; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Weiss J; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
Bulach C; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
Götz M; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
Greiner J; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.; Department of Internal Medicine, Diakonie Hospital Stuttgart, 70176 Stuttgart, Germany.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 26; Vol. 24 (11). Date of Electronic Publication: 2023 May 26.
Typ publikacji:
Journal Article
MeSH Terms:
T-Lymphocytes*
Leukemia, Myeloid, Acute*/pathology
Humans ; Lenalidomide/pharmacology ; Lenalidomide/therapeutic use ; Nivolumab/pharmacology ; Nivolumab/therapeutic use ; Immunotherapy ; Immunity
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
Autorzy:
Abramson HN; Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 27; Vol. 24 (21). Date of Electronic Publication: 2023 Oct 27.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma*/therapy
Antibodies, Bispecific*
Humans ; Quality of Life ; Immunotherapy ; Lenalidomide ; Bortezomib ; Immunotherapy, Adoptive
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma.
Autorzy:
Paikaray SK; All India Institute of Medical Sciences, New Delhi, India.
Gogia A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar L; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Biswas AA; Department of Radiation Oncology, All India Institute of Medical Sciences, AIIMS, New Delhi, India.
Vishnubhatla S; Department of Biostatistics, AIIMS, New Delhi, India.
Mallick S; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Pokaż więcej
Źródło:
Indian journal of cancer [Indian J Cancer] 2023 Oct 01; Vol. 60 (4), pp. 501-504. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Lymphoma, Follicular*/drug therapy
Lymphoma, Follicular*/pathology
Humans ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/therapeutic use ; Lenalidomide/therapeutic use ; Rituximab/therapeutic use ; Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Autorzy:
Zhou Y; Department of Infectious Diseases II, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Wang X; Department of hematology, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Lin X; Department of pathology, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, Liaoning Province, China.
Wang J; Department of neurosurgery, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, Liaoning Province, China.
Yan X; Department of hematology, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China. yanxiaojing_.
Wen Y; Department of Infectious Diseases II, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China. .
Pokaż więcej
Źródło:
AIDS research and therapy [AIDS Res Ther] 2023 Aug 29; Vol. 20 (1), pp. 63. Date of Electronic Publication: 2023 Aug 29.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
HIV Infections*/complications
HIV Infections*/drug therapy
Lymphoma*
Humans ; Agammaglobulinaemia Tyrosine Kinase ; HIV ; Lenalidomide ; Central Nervous System
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Autorzy:
Lucero J; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 700 University Avenue, 6th Floor, Toronto, ON M5G 1Z5, Canada.
Al-Harbi S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 700 University Avenue, 6th Floor, Toronto, ON M5G 1Z5, Canada.
Yee KWL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 700 University Avenue, 6th Floor, Toronto, ON M5G 1Z5, Canada.; Division of Hematology, University of Toronto, Toronto, ON M5S 3H2, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Jun 27; Vol. 30 (7), pp. 6177-6196. Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Myelodysplastic Syndromes*/therapy
Neoplasms*/drug therapy
Humans ; Prognosis ; Lenalidomide/therapeutic use ; Risk ; Immunologic Factors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Maintenance regimen of GM-CSF with rituximab and lenalidomide improves survival in high-risk B-cell lymphoma by modulating natural killer cells.
Autorzy:
Sun S; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Fulati W; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Shen L; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Wu M; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Huang Z; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Qian W; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Chen P; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Hu Y; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Chen M; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Xu Y; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Zhang H; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Ma J; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Xie Y; Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Jun; Vol. 12 (12), pp. 12975-12985. Date of Electronic Publication: 2023 Apr 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Granulocyte-Macrophage Colony-Stimulating Factor*
Lymphoma, B-Cell*/drug therapy
Humans ; Aged ; Rituximab/therapeutic use ; Lenalidomide ; Prospective Studies ; Antibodies, Monoclonal, Murine-Derived ; Killer Cells, Natural ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 6873

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies